Genetic Markers for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether certain genetic changes, specifically TMPRSS2-ERG gene fusion and PTEN deletion, can predict how well men with high-risk prostate cancer respond to a specific hormone therapy after other treatments have failed. The focus is on patients whose cancer has returned after radiation therapy and who are now receiving LHRH agonists, a common hormone therapy for prostate cancer. Suitable candidates for this study have advanced prostate cancer, indicated by a PSA level over 20, a Gleason score of 8 or higher, and the ability to perform daily activities independently. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important advancements in prostate cancer therapy.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to uncover how specific genetic changes, like the TMPRSS2-ERG gene fusion and PTEN deletion, might predict prostate cancer progression after treatments like radiation therapy. Unlike standard treatments that focus on managing symptoms or slowing cancer growth, this trial could lead to more personalized treatment plans by identifying patients who are more likely to benefit from certain therapies. By understanding these genetic markers, doctors could tailor treatments more effectively, potentially improving outcomes for patients with biochemical failure after radiation therapy.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive standard hormonal treatment with LHRH agonist, and may receive additional systemic therapy or radiation therapy for oligometastasis
Follow-up
Participants are monitored for hormonal refractory free survival and clinical progression
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sir Mortimer B. Davis - Jewish General Hospital
Lead Sponsor